Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, No. 28 Xiangya Road, Kai-Fu District, Changsha, 410008, Hunan, People's Republic of China.
Center of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China.
Antimicrob Resist Infect Control. 2022 Dec 19;11(1):161. doi: 10.1186/s13756-022-01204-w.
The prevalence of carbapenem-resistant Klebsiella pneumoniae bloodstream infection (CRKP-BSI) is increasing worldwide. CRKP-BSI is associated with high rates of morbidity and mortality due to limited antibiotic choices. Here, we aim to identify the prevalence and risk factors for infection and mortality of CRKP BSI.
This was a retrospective study of the past data from January 1st, 2012 to December 31st, 2019 of adult patients with KP-BSI in Xiangya Hospital, China.
Among the 706 incidences included in this study, 27.4% of them (212/753) being CR-KP strains. The occurrence of CRKP-BSI was increased from 20.69 to 37.40% from 2012 to 2019. Hematologic malignancies and ICU acquired infection were identified to be substantial risk factors of carbapenem resistance. The overall 28-day mortality rates of CRKP-BSI patients was significantly higher than that of CSKP-BSI (P < 0.001). Logistic regression analysis identified severe sepsis or septic shock incidents, inadequate empirical antimicrobial therapy and corticosteroids use preceding infection onset as the independent predictors of 28-day mortality of CRKP-BSI patients. However, high dose carbapenem combination therapy was identified as anticipated factors of low 28-day mortality.
The occurrence of CRKP-BSI was significantly increased during the study period. Hematologic malignancies and ICU acquired infection were associated with the development of CRKP BSI. Severe sepsis or septic shock incidents, inadequate empirical antimicrobial therapy and corticosteroids use preceding infection onset caused significant increase of mortality rates in CRKP-BSI patients. High dose carbapenem combination therapy was associated with better outcome.
全球范围内耐碳青霉烯类肺炎克雷伯菌血流感染(CRKP-BSI)的患病率正在上升。由于抗生素选择有限,CRKP-BSI 与高发病率和死亡率相关。在这里,我们旨在确定 CRKP BSI 的感染和死亡率的流行率和危险因素。
这是一项回顾性研究,对中国湘雅医院 2012 年 1 月 1 日至 2019 年 12 月 31 日期间成人肺炎克雷伯菌血流感染患者的过去数据进行了研究。
在本研究中包括的 706 例病例中,有 27.4%(212/753)为 CR-KP 株。从 2012 年到 2019 年,CRKP-BSI 的发生率从 20.69%增加到 37.40%。血液恶性肿瘤和 ICU 获得性感染被确定为耐碳青霉烯类药物的重要危险因素。CRKP-BSI 患者的 28 天死亡率明显高于 CSKP-BSI(P<0.001)。Logistic 回归分析确定严重脓毒症或感染性休克事件、经验性抗菌治疗不足和感染前使用皮质类固醇是 CRKP-BSI 患者 28 天死亡率的独立预测因素。然而,高剂量碳青霉烯类药物联合治疗被认为是降低 28 天死亡率的预期因素。
在研究期间,CRKP-BSI 的发生率显著增加。血液恶性肿瘤和 ICU 获得性感染与 CRKP BSI 的发生有关。严重脓毒症或感染性休克事件、经验性抗菌治疗不足和感染前使用皮质类固醇导致 CRKP-BSI 患者死亡率显著增加。高剂量碳青霉烯类药物联合治疗与更好的结果相关。